Atara Biotherapeutics (ATRA) Competitors $7.82 +0.26 (+3.44%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$7.78 -0.04 (-0.58%) As of 05/2/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. HURA, TVGN, ACIU, MOLN, KRRO, IKT, PRQR, TNGX, FDMT, and TLSAShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include TuHURA Biosciences (HURA), Tevogen Bio (TVGN), AC Immune (ACIU), Molecular Partners (MOLN), Korro Bio (KRRO), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), Tango Therapeutics (TNGX), 4D Molecular Therapeutics (FDMT), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. TuHURA Biosciences Tevogen Bio AC Immune Molecular Partners Korro Bio Inhibikase Therapeutics ProQR Therapeutics Tango Therapeutics 4D Molecular Therapeutics Tiziana Life Sciences TuHURA Biosciences (NASDAQ:HURA) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking. Which has better valuation & earnings, HURA or ATRA? TuHURA Biosciences has higher earnings, but lower revenue than Atara Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$8.32MN/AN/AAtara Biotherapeutics$128.94M0.36-$276.13M-$12.97-0.60 Which has more volatility and risk, HURA or ATRA? TuHURA Biosciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Do analysts recommend HURA or ATRA? TuHURA Biosciences currently has a consensus price target of $12.67, suggesting a potential upside of 223.13%. Atara Biotherapeutics has a consensus price target of $17.75, suggesting a potential upside of 126.98%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe TuHURA Biosciences is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Does the MarketBeat Community prefer HURA or ATRA? Atara Biotherapeutics received 433 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 67.33% of users gave Atara Biotherapeutics an outperform vote. CompanyUnderperformOutperformTuHURA BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesAtara BiotherapeuticsOutperform Votes43767.33% Underperform Votes21232.67% Is HURA or ATRA more profitable? TuHURA Biosciences has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A N/A -152.88% Atara Biotherapeutics -132.58%N/A -90.16% Do insiders and institutionals hold more shares of HURA or ATRA? 0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer HURA or ATRA? In the previous week, TuHURA Biosciences had 5 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for TuHURA Biosciences and 0 mentions for Atara Biotherapeutics. TuHURA Biosciences' average media sentiment score of 0.40 beat Atara Biotherapeutics' score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Overall Sentiment TuHURA Biosciences Neutral Atara Biotherapeutics Neutral SummaryTuHURA Biosciences beats Atara Biotherapeutics on 8 of the 13 factors compared between the two stocks. Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.62M$2.97B$5.56B$8.03BDividend YieldN/A1.87%5.09%4.23%P/E Ratio-0.3030.5222.7518.87Price / Sales0.36493.12405.66106.84Price / CashN/A168.6838.1834.62Price / Book-0.323.216.794.34Net Income-$276.13M-$72.35M$3.22B$248.06M7 Day Performance6.83%13.45%3.36%3.18%1 Month Performance32.09%12.30%6.92%8.28%1 Year Performance-53.31%-23.52%16.16%5.04% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics3.6217 of 5 stars$7.82+3.4%$17.75+127.0%-51.9%$46.62M$128.94M-0.30330Upcoming EarningsGap UpHURATuHURA BiosciencesN/A$3.97-3.2%$12.67+219.1%N/A$173.41MN/A0.00N/ATVGNTevogen Bio3.1227 of 5 stars$0.94-5.5%$7.10+657.4%+2.0%$172.38MN/A0.003Analyst ForecastACIUAC Immune2.2859 of 5 stars$1.70+3.7%$12.00+605.9%-29.5%$170.70M$27.31M-3.70140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsMOLNMolecular Partners1.8278 of 5 stars$4.08-2.9%$12.00+194.1%+8.2%$164.73M$4.97M-1.90180Gap UpHigh Trading VolumeKRROKorro Bio1.6825 of 5 stars$17.47-3.4%$120.43+589.3%-64.1%$164.03M$2.27M-1.8670Analyst UpgradeAnalyst RevisionNews CoveragePositive NewsIKTInhibikase Therapeutics1.6494 of 5 stars$2.20+4.3%$6.50+195.5%+67.9%$163.55M$260,000.00-0.826News CoveragePRQRProQR Therapeutics2.9547 of 5 stars$1.54+7.7%$9.50+516.9%+0.0%$162.03M$18.91M-4.81180Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTNGXTango Therapeutics2.4174 of 5 stars$1.49+2.1%$12.33+727.7%-80.1%$161.08M$42.07M-1.2690Upcoming EarningsNews CoveragePositive NewsFDMT4D Molecular Therapeutics2.6803 of 5 stars$3.34flat$26.71+699.8%-85.7%$154.65M$37,000.00-1.17120Upcoming EarningsNews CoverageTLSATiziana Life Sciences0.3269 of 5 stars$1.31-3.7%N/A+81.5%$153.07MN/A0.008Short Interest ↑Gap Down Related Companies and Tools Related Companies HURA Alternatives TVGN Alternatives ACIU Alternatives MOLN Alternatives KRRO Alternatives IKT Alternatives PRQR Alternatives TNGX Alternatives FDMT Alternatives TLSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATRA Stock Free ATRA Stock Alerts